Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer - PubMed (original) (raw)

Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer

Sakshi Sikka et al. PPAR Res. 2012.

Abstract

The peroxisome proliferator-activated receptor-gamma (PPARγ) is a member of the hormone-activated nuclear receptor superfamily. PPARγ can be activated by a diverse group of agents, such as endogenous polyunsaturated fatty acids, 15-deoxy-Δ(12,14)-prostaglandin J(2) (15d-PGJ(2)), and thiazolidinedione (TZD) drugs. PPARγ induces antiproliferative, antiangiogenic, and prodifferentiation pathways in several tissue types, thus making it a highly useful target for downregulation of carcinogenesis. These TZD-derived novel therapeutic agents, alone or in combination with other anticancer drugs, have translational relevance in fostering effective strategies for cancer treatment. TZDs have been proven for antitumor activity in a wide variety of experimental cancer models, both in vitro and in vivo, by affecting the cell cycle, inducing cell differentiation and apoptosis, as well as by inhibiting tumor angiogenesis. Angiogenesis inhibition mechanisms of TZDs include direct inhibition of endothelial cell proliferation and migration, as well as reduction in tumor cell vascular endothelial growth factor production. In prostate cancer, PPARγ ligands such as troglitazone and 15d-PGJ(2) have also shown to inhibit tumor growth. This paper will focus on current discoveries in PPARγ activation, targeting prostate carcinogenesis as well as the role of PPARγ as a possible anticancer therapeutic option. Here, we review PPARγ as an antitumor agent and summarize the antineoplastic effects of PPARγ agonists in prostate cancer.

PubMed Disclaimer

Figures

Figure 1

Figure 1

PPAR_γ_ activity. Upon ligand binding PPAR_γ_, binds to RXR in the nucleus and associates with coactivators to bind PPRE located on target genes that control various activities.

Similar articles

Cited by

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer Journal for Clinicians. 2008;58(2):71–96. - PubMed
    1. Hirsch J, Johnson CL, Nelius T, Kennedy R, Riese WD, Filleur S. PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ . Cytokine. 2011;55(2):202–210. - PubMed
    1. Akinyeke TO, Stewart LV. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism. Cancer Biology and Therapy. 2011;11(12):1046–1058. - PMC - PubMed
    1. Nelson PS, Clegg N, Arnold H, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(18):11890–11895. - PMC - PubMed
    1. Lehrke M, Lazar MA. The many faces of PPARγ . Cell. 2005;123(6):993–999. - PubMed

LinkOut - more resources